A similar effect might be responsible for inferior PFS in NHL, for which doxorubicin is an essential part of most chemotherapy regimens; however, this hypothesis needs to be further investigated by LOH analyses in NHL tumor specimens of CHEK2 hereditary mutation carriers (not available in our study) and especially by in vivo models. Here, CHEK2 is linked to non-Hodgkin lymphoma.